Alzheimer’s disease (AD) therapeutics – 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality-Reference-Cited by-同舟云学术

Alzheimer’s disease (AD) therapeutics – 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality

Published:2018-12 Issue: Volume:158 Page:359-375
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Mullane Kevin,Williams Michael

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference243 articles.

1. Dementia prevention, intervention, and care;Livingston;Lancet,2017

2. The worldwide costs of dementia 2015 and comparisons with 2010;Wimo;Alzheimer’s Dementia,2017

3. The cost of Alzheimer's disease in China and re-estimation of costs worldwide;Jia;Alzheimer’s Dementia,2018

4. Drug development in Alzheimer’s disease: the path to 2025;Cummings;Alzheim. Res. Ther.,2016

5. D.H. Freedman, The missing Alzheimer’s pill, Politico Agenda 2020, December 13, 2017. Available from: .

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in Understanding and Managing Alzheimer's Disease: from Pathogenesis to Treatment;Revista de Gestão Social e Ambiental;2024-06-25

2. Euonymus alatus and its compounds suppress hydrogen peroxide-induced oxidative stress in HT22 cells;Food Science and Biotechnology;2024-06-08

3. Probing Protein Structural Changes in Alzheimer’s Disease via Quantitative Cross-linking Mass Spectrometry;Analytical Chemistry;2024-05-01

4. Alzheimer’s Disease: A Molecular Model and Implied Path to Improved Therapy;International Journal of Molecular Sciences;2024-03-20

5. Unveiling Nature’s Arsenal: Natural Sources for Drug Discovery in Alzheimer’s Disease;Drugs from Nature: Targets, Assay Systems and Leads;2024